GREGORY R HOOK
- Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeuticsGregory Hook
American Life Science Pharmaceuticals Inc, San Diego, CA 92121, USA
Biol Chem 388:979-83. 2007..The results suggest that cysteine protease inhibitors generally, and reversible cysteine protease inhibitors specifically, have potential for development as AD therapeutics...
- The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activityGregory Hook
American Life Science Pharmaceuticals, San Diego, CA 92109, USA
J Alzheimers Dis 26:387-408. 2011..We conclude that E64d likely reduces brain Aβ by inhibiting cathepsin B and not BACE1 β-secretase activity and that E64d therefore may have potential for treating AD patients...
- Beta-Secretase Assays to Discover Drugs for Alzheimer'sGregory Hook; Fiscal Year: 2004..ActiveSite Biotech is in a position to exclusively sell, license, or partner lead drug inhibitors resulting from the Phase II study. ..
- Gamma Secretase Assays to Discover Drugs for Alzheimer'sGregory Hook; Fiscal Year: 2006..Results will likely identify novel lead compounds for future pre-clinical animal studies for development of effective drugs for AD. ..
- Inhibitors of beta-Amyloid Production in Alzheimer'sGregory Hook; Fiscal Year: 2007..Specifically, we will assess the affects of these peptidomimetics on beta-amyloid secretion in primary neuronal cultures and in vivo. ..